Short answer
Niagen Bioscience, Inc. (NAGE) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $30M (down 4.3% year over year) with net income of $963,000.
Q2 2026 key financials · XBRL
- Revenue
- $30M
- −4.3% YoY · −5.4% QoQ
- Net income
- $963,000
- −73.3% YoY · −84.8% QoQ
- Operating margin
- 2.4%
- Gross margin
- 64.8%
- EPS (diluted)
- $0.02
- −50.0% YoY · −71.4% QoQ
Source: XBRL data from the Niagen Bioscience, Inc. (NAGE) Q2 2026 10-Q on SEC EDGAR. USD.
Niagen Bioscience, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $29.785M, down 4% YoY from $31.117M
- Consumer Products best performer: revenue $24.162M, up 6% YoY; Ingredients $5.387M, down 29%
- Gross margin 64.8% vs 65.0% YoY; operating expenses 34.0% of sales vs 26.4%
- Cash $66.7M, including $66.6M unrestricted; $1.3M previously withheld receivables collected
- Near-term headwinds: softer partner demand, order timing variability, competitive pricing, and temporary recall-related costs
Risk Factors
- New competitive risk: FDA’s September 2025 NMN determination enabled lawful dietary-ingredient marketing, intensifying lower-priced competition
- NMN litigation risk: Company challenged FDA’s interpretation, but outcome and timing remain unpredictable
- Near-term market risk: NMN competition has already affected ingredient-business financial results since September 2025
- Customer concentration risk: Major-customer declines could disproportionately reduce ingredient revenue, margins, and results
- Financial risk: Additional capital may be needed within twelve months, with potential dilution or unfavorable financing terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Niagen Bioscience, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.